Please try another search
Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It is developing Northera (droxidopa), a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (Neurogenic OH) in patients with primary autonomic failure, dopamine-ß-hydroxylase, and deficiency and non-diabetic autonomic neuropathy. The company is also evaluating droxidopa in other potentially norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, freezing of gait, and adult attention deficit hyperactivity disorders. In addition, it is has a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis, as well as for the treatment of multiple other autoimmune disorders, including psoriasis, Crohn’s diseases, uveitis, ankylosing spondylitis, inflammatory bowel diseases, cancer, and other immunological disorders. The company was founded in 2002 and is headquartered in Charlotte, North Carolina. As of June 23, 2014, Chelsea Therapeutics International Ltd. operates as a subsidiary of H. Lundbeck A/S.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review